Videos

An expert discusses how moving lurbinectedin to earlier in treatment is justified because 40% to 50% of patients with small cell lung cancer (SCLC) never receive second-line therapy due to rapid disease progression, making proactive treatment essential.

An expert discusses efforts to improve the tolerability and delivery of the MARIPOSA regimen, highlighting subcutaneous amivantamab from the Paloma studies and proactive skin care strategies from the Cocoon study as key advances in enhancing patient experience, adherence, and clinical outcomes.

An expert discusses how lurbinectedin maintenance therapy causes primarily hematologic toxicities but has a low discontinuation rate (6.2%), making it suitable for most patients with good performance status and adequate blood count recovery.

Harpreet Singh, MD, former FDA director, discusses the FDA's new draft guidance on radiopharmaceutical dosing and its relation to Project Optimus.

Dr. Gerrina Ruiter discusses zongertinib's promising efficacy in treating HER2-mutant NSCLC, highlighting its unique effectiveness against brain metastases.

Innovative advancements in cell therapy enhance NK cells for solid tumors, aiming for effective treatments while prioritizing patient safety and clinical success.

Chandler H. Park, MD, discusses NCCN treatment regimens for patients with metastatic bladder cancer.

Discover how El Camino Health's multidisciplinary approach enhances cancer care for younger adults, featuring collaboration among diverse medical specialists.

Gerrina Ruiter, MD, PhD, highlights the Beamion LUNG-1 study's impact on treating HER2-mutant non-small cell lung cancer with brain metastases.

Katy Rezvani, MD, PhD, discusses advancements in CAR-NK cell therapy, focusing on enhancing antitumor efficacy while ensuring safety through precise gene editing techniques.

Dr Katy Rezvani reveals groundbreaking insights on enhancing CAR-NK cell therapy's effectiveness against solid tumors through innovative genetic strategies.

Katy Rezvani, MD, PhD, explores innovative CAR-NK cell therapies, highlighting their potential to overcome challenges in treating solid tumors and enhancing cancer treatment efficacy.

Andrew M. Brunner, MD, discusses the mechanism of action of telomerase inhibitors as treatment for anemia related to myelodysplastic syndrome.

Early-stage squamous cell carcinoma of the esophagus is primarily treated with endoscopic resection, while esophagectomy or chemoradiotherapy may be considered for select patients based on staging and overall health.

Shane Dormady, MD, discusses the unique emotional care needs of young adults with cancer, emphasizing hope and holistic support for better outcomes.

An expert discusses how the IMforte trial demonstrated that adding lurbinectedin to maintenance atezolizumab significantly improved progression-free survival (2.1 to 5.4 months) and overall survival (10.6 to 13.2 months) with an HR of 0.73.

An expert discusses how the IMpower133 trial established atezolizumab plus chemotherapy as standard care for extensive-stage small cell lung cancer (ES-SCLC), improving overall survival from 10.3 to 12.3 months, though most patients still don't achieve long-term survival.

An expert discusses the MARIPOSA study’s impact on managing central nervous system (CNS) involvement in EGFR-mutated non–small cell lung cancer, emphasizing improved brain progression-free survival, dual-targeted resistance prevention, and a promising shift toward more effective and personalized treatment strategies.

Discover how zipalertinib, an oral TKI, addresses unmet needs in treating EGFR exon 20 insertion-mutated non-small cell lung cancer.

Experts explore innovative therapies for high-risk smoldering multiple myeloma, aiming to delay progression and enhance patient outcomes through early intervention.

Petros Grivas, MD, PhD, discusses how the JAVELIN Bladder 100 trial established avelumab as standard maintenance therapy for advanced bladder cancer.

Paula Rodriguez Otero, MD, PhD, discusses promising results of linvoseltamab in high-risk smoldering multiple myeloma, highlighting its potential to prevent disease progression.

Paula Rodriguez Otero, MD, PhD, discusses linvoseltamab's manageable safety profile in high-risk smoldering multiple myeloma, highlighting promising study results.

A phase 2 study evaluates linvoseltamab's safety and efficacy in high-risk smoldering myeloma, focusing on response rates and MRD negativity.

Prostate cancer advancements highlight genetic mutations' impact on therapy and family health, emphasizing early treatment strategies for better outcomes.

Experts explore the evolving treatment strategies for high-risk smoldering multiple myeloma, highlighting studies that show early intervention can improve patient outcomes.

New findings reveal tarlatamab combined with anti–PD-L1 agents significantly improves survival in extensive-stage small cell lung cancer, prompting further research.

An expert discusses emerging frontline treatments for EGFR-mutated non–small cell lung cancer (NSCLC), highlighting the evolving role of regimens like FLORA2 and MARIPOSA, and emphasizing the shift toward personalized, patient-centered therapy strategies.

Discover how recent studies shift minimal residual disease testing from a prognostic tool to a key player in managing hematological malignancies.

Dr Kelly Paulson shares groundbreaking insights from the DeLLphi-303 study, highlighting new immunotherapy strategies for small cell lung cancer treatment.